Galapagos Acquires Cangenix
News Jan 16, 2013
Galapagos NV and Cangenix Ltd have announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering.
Cangenix’s technology will augment Argenta’s ability to design new drugs and fill a growing client need.
Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 potential earn out payment contingent upon achievement of certain conditions.
Argenta will integrate all of Cangenix’s assets, know-how, personnel and service contracts. The activities will be added to Argenta’s capabilities in hit finding and medicinal chemistry.
The Cangenix team of 4 staff will join Argenta but will continue to operate the platform in its premises in Canterbury, securing a smooth transition of the business. The acquisition will contribute to the Argenta revenues and profit for 2013.
“We welcome the Cangenix team and their clients to the Galapagos group,” said Onno van de Stolpe, CEO of Galapagos. “The assets and expertise of Cangenix really address a growing client need at Argenta. We look forward to extending and expanding this business.”
“I am confident that Cangenix’s expertise in structure-based drug discovery services will enable Argenta to design better drugs for clients,” added Prof David Brown, CEO, Cangenix Ltd.
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
High-throughput Screening: Microscale Thermophoresis to Characterize HitsNews
A new perspective article details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018